This interaction promotes TAM recruitment and an immunosuppressive phenotype, thereby protecting the tumor from cytotoxic T-cell infiltration and rendering it resistant to immune checkpoint blockade (ICB) therapies, such as anti-PD-1.457 Interferon-Induced Protein 35 (IFI35) recruits TAMs through the proteasomal regulation of non-classical NF-κB signaling via p105458 in glioblastoma. Here, IFI35 is linked to glioblastoma.